PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved Oct. 23, 2025 for two new employees under Nasdaq Listing Rule 5635(c)(4).
The company granted non-statutory stock options to purchase an aggregate of 2,000 shares and 1,990 restricted stock units (RSUs). Options have an exercise price of $66.80 (closing price on Oct. 23, 2025), a 10-year term, and vest over four years: 25% at the first anniversary then 6.25% quarterly thereafter. RSUs vest over four years with 25% vesting on each annual anniversary. Grants were approved by the Compensation Committee and made as inducements to accept employment.
Positive
- None.
Negative
- None.
News Market Reaction – PTCT
On the day this news was published, PTCT gained 0.61%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The inducement grants were approved by PTC's Compensation Committee on Oct. 23, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on Facebook, X, and LinkedIn.
For more information, please contact:
Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302595071.html
SOURCE PTC Therapeutics, Inc.